Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Optimisation of pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives as novel Hsp90 C-terminal domain inhibitors against Ewing sarcoma
ID
Zajec, Živa
(
Author
),
ID
Dernovšek, Jaka
(
Author
),
ID
Distel, Martin
(
Author
),
ID
Gobec, Martina
(
Author
),
ID
Tomašič, Tihomir
(
Author
)
PDF - Presentation file,
Download
(3,11 MB)
MD5: F5A22E168EBA873144FDBCFED68212AB
URL - Source URL, Visit
https://www.sciencedirect.com/science/article/pii/S0045206822007179
Image galllery
Abstract
Ewing sarcoma is the second most prevalent paediatric malignant bone tumour. In most cases, it is driven by the fusion oncoprotein EWS::FLI1, which acts as an aberrant transcription factor and dysregulates gene expression. EWS::FLI1 and a large number of downstream dysregulated proteins are Hsp90 client proteins, making Hsp90 an attractive target for the treatment of Ewing sarcoma. In this article, we report a new structural class of allosteric Hsp90 C-terminal domain (CTD) inhibitors based on the virtual screening hit TVS24, which showed antiproliferative activity in the SK-N-MC Ewing sarcoma cell line with an IC$_{50}$ value of 15.9 ± 0.7 µM. The optimised compounds showed enhanced anticancer activity in the SK-N-MC cell line. Exposure of Ewing sarcoma cells to the most potent analogue 11c resulted in depletion of critical Hsp90 client proteins involved in cancer pathways such as EWS::FLI1, CDK4, RAF-1 and IGF1R, without inducing a heat shock response. The results of this study highlight Hsp90 CTD inhibitors as promising new agents for the treatment of Ewing sarcoma.
Language:
English
Keywords:
cancer
,
Ewing sarcoma
,
Hsp90
,
inhibitor
,
molecular modelling
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
FFA - Faculty of Pharmacy
Publication status:
Published
Publication version:
Version of Record
Year:
2023
Number of pages:
16 str.
Numbering:
Vol. 131, art. 106311
PID:
20.500.12556/RUL-143238
UDC:
615.2:616-006.34
ISSN on article:
0045-2068
DOI:
10.1016/j.bioorg.2022.106311
COBISS.SI-ID:
132438019
Publication date in RUL:
09.12.2022
Views:
1223
Downloads:
137
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Bioorganic chemistry
Shortened title:
Bioorg. chem.
Publisher:
Elsevier
ISSN:
0045-2068
COBISS.SI-ID:
25099008
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Secondary language
Language:
Slovenian
Keywords:
Ewingov sarkom
,
Hsp90
,
inhibitorji
,
molekularno modeliranje
,
maligni tumor kosti
,
rak
,
medicina
,
osteosarkom
Projects
Funder:
ARRS - Slovenian Research Agency
Project number:
P1-0208
Name:
Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin
Funder:
ARRS - Slovenian Research Agency
Project number:
J1-1717
Name:
Razvoj novih zaviralcev Hsp90 s protitumornim delovanjem
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back